BiotechTube

SHR2285 tablet + Placebo

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Thrombosis

Conditions

Thrombosis

Trial Timeline

Aug 28, 2020 → May 31, 2021

NCT ID
NCT04472819

About SHR2285 tablet + Placebo

SHR2285 tablet + Placebo is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Thrombosis. The current trial status is completed. This product is registered under clinical trial identifier NCT04472819. Target conditions include Thrombosis.

What happened to similar drugs?

8 of 20 similar drugs in Thrombosis were approved

Approved (8) Terminated (4) Active (11)
✅Alteplase "push" protocol + alteplase dwell armRocheApproved
✅Dalteparin sodium injection + WarfarinPfizerApproved
✅Low Molecular Weight Heparin (dalteparin)PfizerApproved
✅ApixabanPfizerApproved
✅ClexaneSanofiApproved
✅aspirin 75 mg/daySanofiApproved
✅enoxaparinSanofiApproved

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (2)

NCT IDPhaseStatus
NCT04472819Phase 1Completed
NCT04229433Phase 1Completed

Competing Products

20 competing products in Thrombosis

See all competitors
ProductCompanyStageHype Score
CS1-Sodium ValproateCereno ScientificPhase 1
23
Edoxaban low dose + Edoxaban high doseDaiichi SankyoPhase 1
29
DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitorDaiichi SankyoPhase 2
35
edoxaban tosylate + enoxaparin/unfractionated heparin + warfarinDaiichi SankyoPhase 2
35
Rivaroxaban (Xarelto, BAY59-7939)Johnson & JohnsonPhase 2
35
Warfarin (Coumadin) + Rivaroxaban (Xarelto, BAY59-7939) + Placebo + Vitamin K (Konakion)Johnson & JohnsonPhase 1
29
Rivaroxaban (Xarelto, BAY59-7939) + Enoxaparin followed by VKAJohnson & JohnsonPhase 3
40
SHR2285 + PlaceboJiangsu Hengrui MedicinePhase 1
29
Aspirin、clopidogrel、placebo or SHR2285 + Aspirin、clopidogrel、placebo or SHR2285 + Aspirin、ticagrelor、placebo or SHR2285Jiangsu Hengrui MedicinePhase 1
29
Rosuvastatin (AZD4522) + PlaceboAstraZenecaPhase 3
32
MK-2060 + PlaceboMerckPhase 1
29
dabigatran etexilate + rivaroxabanMerckPhase 1
29
Alteplase "push" protocol + alteplase dwell armRocheApproved
35
Apixaban IR + Apixaban MR1 + Apixaban MR2 + Apixaban MR3PfizerPhase 1
29
Enoxaparin + warfarin + Placebo for apixaban + Placebo for enoxaparin + Placebo for warfarin + apixabanPfizerPhase 3
40
Apixaban + PlaceboPfizerPhase 3
40
90ug levonorgestrel / 20 ug ethinyl estradiol + Oral Contraceptives containing 20 ug of ethinyl estradiolPfizerPre-clinical
26
Fragmin (dalteparin sodium )PfizerPre-clinical
26
PD 0348292 + EnoxaparinPfizerPhase 2
35
Dalteparin + WarfarinPfizerPhase 2
35